Ratings BerGenBio ASA

Equities

BGBIO

NO0013251173

Real-time Oslo Bors Other stock markets 09:09:07 2024-07-12 am EDT			5-day change	1st Jan Change
12.18 ^NOK	-2.93%		+6.30%	-56.18%

May. 29	BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 29	Transcript : BerGenBio ASA, Q1 2024 Earnings Call, May 29, 2024

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BERGENBIO ASA	-56.18%	45.79M	-
VERTEX PHARMACEUTICALS INCORPORATED	+20.95%	127B	B+
REGENERON PHARMACEUTICALS, INC.	+23.00%	117B	B+
ARGENX SE	+24.66%	27.77B	B
BIONTECH SE	-19.75%	20.44B	B+
GENMAB A/S	-15.15%	16.62B	A-
BEIGENE, LTD.	-16.56%	15.92B	B
WUXI APPTEC CO., LTD.	-46.65%	14.94B	A-
NEUROCRINE BIOSCIENCES, INC.	+11.19%	14.74B	C+
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes